Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the trial is to study the efficacy and safety of treatment with BDB-001 Injection substitution of glucocorticoid in patients with ANCA-associated vasculitis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Experimental | BDB-001 injection low dose plus reduced dose glucocorticoids in combination with cyclophosphamide |
|
| Group B | Experimental | BDB-001 injection high dose plus reduced dose glucocorticoids in combination with cyclophosphamide |
|
| Group C | Active Comparator | Standard dose glucocorticoids in combination with cyclophosphamide |
|
| Group D | Experimental | BDB-001 injection low dose in combination with cyclophosphamide |
|
| Group E | Experimental | BDB-001 injection high dose in combination with cyclophosphamide |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BDB-001 injection | Drug | Intravenously administered |
|
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of patients achieving disease complete remission or partial remission assessed by Birmingham Vasculitis Activity Score (BVAS) | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of patients achieving disease complete remission assessed by Birmingham Vasculitis Activity Score (BVAS) | 12 weeks | |
| Change from baseline in the Birmingham Vasculitis Activity Score (BVAS) | 4 weeks、8 weeks、12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Minghui Zhao, Postdoc | Peking University First Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Second hospital Of Anhui Medical University | Hefei | Anhui | 230601 | China | ||
| Peking Union Medical College Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cyclophosphamide | Drug | Intravenously administered |
|
| Glucocorticoids | Drug | Orally administered |
|
|
| Change from baseline in the Vasculitis Damage Index (VDI) | 12 weeks |
| Change from baseline in Estimated glomerular filtration rate (eGFR)、Urinary albumin:creatinine ratio (UACR)、Urine erythrocyte | 4 weeks、8 weeks、12 weeks |
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. | Safety and tolerability indexes of BDB-001 injection for multiple administration of ANCA-associated vasculitis(AAV) patients | 0-24weeks |
| Number of Participants developing anti-BDB-001 antibodies. | Safety and tolerability indexes of BDB-001 injection for multiple administration of ANCA-associated vasculitis(AAV) patients | 0-24weeks |
| Area under the plasma concentration versus time curve (AUC) of BDB-001. | Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis. | 0-12 weeks |
| Peak Plasma Concentration (Cmax) of BDB-001 and time to reach Cmax. | Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis. | 0-12 weeks |
| Minimal Plasma Concentration (Cmin) of BDB-001. | Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis. | 0-12 weeks |
| Terminal phase half-life. | Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis. | 0-12 weeks |
| Change from baseline in C5a (mg/dL) concentration. | 0-12 weeks |
| Beijing |
| Beijing Municipality |
| 100005 |
| China |
| Peking University First Hospital | Beijing | Beijing Municipality | 100034 | China |
| Peking University International Hospital | Beijing | Beijing Municipality | 102206 | China |
| Guangxi Academy of Medical Sciences,The People's Hospital of Guangxi Zhuang Autonomous Region | Nanning | Guangxi Zhuang Autonomous Region (gzar) | 530016 | China |
| The Second hospital of Hebei Medical University | Shijiazhuang | Hebei | 050004 | China |
| The Third hospital of Hebei Medical University | Shijiazhuang | Hebei | 050051 | China |
| The First Affiliated Hospital of Henan University of science and Technology | Luoyang | Henan | 471003 | China |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan | 450052 | China |
| Tongji Hospital,Tongji Medical college of Hust | Wuhan | Hubei | 100005 | China |
| Xiangya Hospital Central South University (Nephrology Department) | Changsha | Hunan | 410008 | China |
| Xiangya Hospital Central South University(Rheumatism Immunity Branch) | Changsha | Hunan | 410008 | China |
| The Third Xiangya Hospital of Central South University | Changsha | Hunan | 410205 | China |
| The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi | 330006 | China |
| Shengjing Hospital of China Medical University | Shengyang | Liaoning | 110004 | China |
| The First Hospital of China Medical University | Shenyang | Liaoning | 110001 | China |
| General Hospital of Ningxia Medical University | Yinchuan | Ningxia Hui Autonomous Region(NHAR) | 750003 | China |
| Zhongshan hospital,Fudan University | Shanghai | Shanghai Municipality | 200032 | China |
| Xijing Hospital | Xi’an | Shanxi | 710032 | China |
| The First Affiliated Hospital of Xi'an Jiao Tong University | Xi’an | Shanxi | 710061 | China |
| Tianjin Medical University General Hospital | Tianjin | Tianjin Municipality | 300052 | China |
| The First Affiliated Hospital, College of Medicine, Zhejiang University | Hangzhou | Zhejiang | 310003 | China |
| ID | Term |
|---|---|
| D056648 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis |
| ID | Term |
|---|---|
| D056647 | Systemic Vasculitis |
| D014657 | Vasculitis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000719787 | BDB001 |
| D003520 | Cyclophosphamide |
| D005938 | Glucocorticoids |
| D011241 | Prednisone |
| ID | Term |
|---|---|
| D010752 | Phosphoramide Mustards |
| D009588 | Nitrogen Mustard Compounds |
| D009150 | Mustard Compounds |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D063088 | Phosphoramides |
| D009943 | Organophosphorus Compounds |
| D000305 | Adrenal Cortex Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D011244 | Pregnadienediols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided